Related Experiment Video

Updated: Jun 4, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment

Patrick A Ott1, Sylvia Adams

  • 1New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY 10016, USA. patrick.ott@nyumc.org

Immunotherapy
|February 17, 2011
PubMed

Insights

Small-molecule inhibitors targeting oncogenic pathways impact immune cells. This review explores how inhibitors of MAPK, AKT-PI3K-mTOR, and VEGF-VEGFR pathways modulate immune responses in cancer therapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Oncogenic signaling pathways are crucial in cancer development.
  • Small-molecule inhibitors targeting these pathways are used in cancer therapy.
  • These pathways also play roles in immune cell signaling and interactions.

Purpose of the Study:

  • To highlight the impact of small-molecule inhibitors on immune function.
  • To discuss exemplary pathways: MAPK, AKT-PI3K-mTOR, and VEGF-VEGFR.
  • To review inhibitors affecting T cells and dendritic cells.

Main Methods:

  • Literature review of signaling pathways and small-molecule inhibitors.
  • Focus on pathways MAPK, AKT-PI3K-mTOR, and VEGF-VEGFR.
  • Analysis of studies investigating inhibitor effects on immune cells.

Main Results:

  • Small-molecule inhibitors can significantly influence immune responses, both stimulating and suppressing.
  • Inhibitors targeting key oncogenic pathways affect immune cell function.
  • Specific examples illustrate the modulation of immune activity.

Conclusions:

  • Inhibition of signaling molecules is vital for modulating immune function in cancer treatment.
  • Understanding these effects is crucial for optimizing cancer therapy.
  • Further research is needed to fully elucidate these complex interactions.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...